- Home
- REBN vs ALLR Comparison
REBN vs ALLR Comparison
Compare REBN & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- ALLR
- Stock Information
- Founded
- REBN 2015
- ALLR 2004
- Country
- REBN United States
- ALLR United States
- Employees
- REBN N/A
- ALLR N/A
- Industry
- REBN Restaurants
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- ALLR Health Care
- Exchange
- REBN Nasdaq
- ALLR Nasdaq
- Market Cap
- REBN 15.3M
- ALLR 15.8M
- IPO Year
- REBN 2022
- ALLR N/A
- Fundamental
- Price
- REBN $2.45
- ALLR $1.73
- Analyst Decision
- REBN
- ALLR Strong Buy
- Analyst Count
- REBN 0
- ALLR 1
- Target Price
- REBN N/A
- ALLR $9.00
- AVG Volume (30 Days)
- REBN 93.6K
- ALLR 21.2M
- Earning Date
- REBN 08-14-2025
- ALLR 08-15-2025
- Dividend Yield
- REBN N/A
- ALLR N/A
- EPS Growth
- REBN N/A
- ALLR N/A
- EPS
- REBN N/A
- ALLR N/A
- Revenue
- REBN $6,565,623.00
- ALLR N/A
- Revenue This Year
- REBN $335.98
- ALLR N/A
- Revenue Next Year
- REBN N/A
- ALLR N/A
- P/E Ratio
- REBN N/A
- ALLR N/A
- Revenue Growth
- REBN 14.03
- ALLR N/A
- 52 Week Low
- REBN $1.03
- ALLR $0.61
- 52 Week High
- REBN $8.30
- ALLR $5.20
- Technical
- Relative Strength Index (RSI)
- REBN 34.79
- ALLR 73.94
- Support Level
- REBN $2.91
- ALLR $1.36
- Resistance Level
- REBN $3.24
- ALLR $1.77
- Average True Range (ATR)
- REBN 0.19
- ALLR 0.21
- MACD
- REBN -0.06
- ALLR 0.08
- Stochastic Oscillator
- REBN 10.91
- ALLR 58.94
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.